engleski

TNF-α-308 and TNF-α-238 polymorphisms in patients with lung cancer as second primary tumor

Objective: There is no evidence that primary lung cancer is different from a second primary lung cancer (SPLC). This study attemps to determine whether SPLCs are different from sporadic cancers in clinical as well in genetic features. The purpose was quantitative evaluation of the association between TNF-α gene polymorphism at site -308 and -238 and lung cancer as a second primary cancer susceptibility. Method: 104 patients with SPLC, 98 non-small cell lung cancer (NSCLC) and 6 small cell lung cancer (SCLC), were investigated. 201 unrelated first primary lung cancer patients, 174 NSCLC and 27 SCLC, were taken as control subjects. TNF-α-308 and TNF-α-238 polymorphisms were investigated in both test group. Results: 70 patients were male and 34 were female. The average age of control group patients was 59.4 years, and SPLC was 68.3 years. Disease free interval (DFI) between first tumor and SPLC was 9.2 years in average. In this, the difference between males and females was significant (6.7 versus 13.5 years ; p<0.001). We did not find any association between particular genotypes and DFI. There was no statistically significant difference between distribution of TNF-α-308 polymorphism genotype and the allele between lung cancer patients with first primary and second primary carcinoma. However, the distribution of TNF-α-238 polymorphism GG genotype and the G allele in SPLC in relation to first primary lung cancer was almost statistically significantly higher (p=0.054 and p=0.057, respectively). The group of second primary NSCLC in relation to first primary NSCLC had more frequent TNF-α-238 polymorphism GG genotype (the difference approached statistical significance, p=0.060) and the G allele (the difference approached statistical significance, p=0.064). When comparing second primary SCLC and first primary SCLC there was no statistically significant difference in distribution of TNF-α-238 polymorphism GG genotype and the G allele. All 104 patients with SPLC had TNF-α-238 GG genotype and the G allele. Conclusion: Cancer free interval between the tumors was significantly longer in females. Second primary NSCLC in relation to first primary NSCLC had more frequent TNF-α-238 polymorphism GG genotype and the G allele. TNF-α-238 GG genotype could have a promotive effect for SPLC, particularly for NSCLC.

TNF; polymorphisms; lung cancer; second primary tumor

nije evidentirano